August 25, 2015 | Saudi Arabia, emerging markets
Published in eyeforpharma 20 May by Rachel Howard
What are the opportunities and challenges for pharma companies wishing to gain a foothold in this oil-rich kingdom?
Traditionally the Middle East and North Africa (MENA) region has been overlooked by pharmaceutical companies, with the region contributing only about 2% of global pharmaceutical sales in 2010. Difficult regulatory environments and political turmoil have compounded the perceived lack of attractiveness of the region as a whole.
As we reach the middle of the decade, could the tide be turning? Over the last year, I have noticed increasing industry interest in Saudi Arabia (KSA) – and with good reason given it is the fastest growing pharmaceutical market in the Middle East, experiencing double-digit growth. In this article, I will take a look at the opportunities and challenges for pharma companies wishing to gain a foothold in this oil-rich kingdom.
Background
Though vast swathes of the country are uninhabitable desert, Saudi Arabia has a population fast approaching 30 million. It is a young country, with over half of the population under 30 years of age. As it is home to the holy Islamic cities of Mecca and Medina, its population receives a seasonal boost as over two million pilgrims visit each year to perform the Hajj. It also contains about a quarter of the world’s known petroleum reserves, and oil revenues account for approximately 90 percent of the government’s income.
A key pillar of Saudi Arabia’s internal stability relative to much of the surrounding region has been the kingdom’s generous social welfare system, of which healthcare forms an important segment. Healthcare services are available free of charge not only to Saudi citizens but also to all pilgrims, regardless of their nationality. Recent decades have seen considerable improvement in both the quantity and quality of healthcare services. A Royal Decree in 2002 resulted in sizeable expansion of the primary care network. Care in the top public hospitals, such as Riyadh’s renowned King Fahad Medical City, easily rivals that of the West, with imported medical technology and state-of-the-art facilities. Medical education is also fully funded by the state, including overseas training. As a result, many physicians are trained in leading US and UK medical schools.
However, not all is rosy. Despite the country’s affluence and stated commitment to healthcare, indicators suggest Saudi Arabia’s overall healthcare performance remains mediocre compared with the West, with an infant mortality rate that is double the average and a shorter life expectancy.
Read the full article at http://www.researchpartnership.com/news/2015/05/spotlight-on-saudi-arabia/
This content was provided by Inizio
Latest Content from Inizio
Pegasus, an Ashfield company, part of UDG Healthcare plc, is delighted to have won the Excellence In Integrated Product/Brand Communications award at the 2017 Communiqué awards for its work with…
We were delighted to present, exhibit and sponsor this year’s EphMRA Annual Conference in Amsterdam, Netherlands.
Directors Phil Rosenberg and Chris Gaj discuss ways to achieve qualitative insights with quantitative precision and the benefits of a hybrid approach.Watch the video:Â https://www.researchpartnership.com/news/2017/06/video-taking-a-hybrid-qualitative-quantitative-appr…
We recently celebrated our 20th year anniversary with parties for our employees across the globe.Find out more and view the photos https://www.researchpartnership.com/news/2017/06/20th-anniversary-party-photos/
13-14 July 2017, Singapore
We are delighted to announce that Research Partnership’s Richard Head is joint winner of the 2017 EphMRA President’s Award for his contribution to pharmaceutical market research
We are delighted to announce that Forever Angels founder Amy Hathaway has been awarded an MBE in this year’s Queen’s Birthday Honours list for providing interim and community care to…
We are delighted to announce that our Asia-Pacific team in Singapore has relocated to new premises.
Published in eyeforpharma June 2017 by Marc Yates
Living with Ulcerative Colitis (UC) is a study conducted amongst 100 adult UC patients in the US. The study employs a mixed quantitative/qualitative methodology and will be available to purchase…
